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Abstract
Proteins are essential macromolecules of life that carry out most cellular processes. Since proteins aggregate to perform
function, and since protein-protein interaction (PPI) networks model these aggregations, one would expect to uncover new
biology from PPI network topology. Hence, using PPI networks to predict protein function and role of protein pathways in
disease has received attention. A debate remains open about whether network properties of ‘‘biologically central (BC)’’
genes (i.e., their protein products), such as those involved in aging, cancer, infectious diseases, or signaling and drug-
targeted pathways, exhibit some topological centrality compared to the rest of the proteins in the human PPI network. To
help resolve this debate, we design new network-based approaches and apply them to get new insight into biological
function and disease. We hypothesize that BC genes have a topologically central (TC) role in the human PPI network. We
propose two different concepts of topological centrality. We design a new centrality measure to capture complex wirings of
proteins in the network that identifies as TC those proteins that reside in dense extended network neighborhoods. Also, we
use the notion of domination and find dominating sets (DSs) in the PPI network, i.e., sets of proteins such that every protein
is either in the DS or is a neighbor of the DS. Clearly, a DS has a TC role, as it enables efficient communication between
different network parts. We find statistically significant enrichment in BC genes of TC nodes and outperform the existing
methods indicating that genes involved in key biological processes occupy topologically complex and dense regions of the
network and correspond to its ‘‘spine’’ that connects all other network parts and can thus pass cellular signals efficiently
throughout the network. To our knowledge, this is the first study that explores domination in the context of PPI networks.
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Introduction
A network (or a graph) is a set of nodes (or vertices), and edges (or links)
between the nodes. Networks enable studying the properties of
complex systems that emerge from interactions among individual
parts. Hence, networks have been used to model and analyze
many real-world phenomena in numerous domains. Examples
include social, technological, transportation, information, finan-
cial, ecological, chemical, and biological systems. We focus on
molecular interaction networks, with the goal of understanding
complex cellular functioning by studying cells as inter-connected
systems rather than as a collection of individual constituents [1].
Nodes in these networks represent biomolecules, such as genes,
proteins, or metabolites, and edges connecting the nodes indicate
functional, physical, or chemical interactions between the
corresponding biomolecules. Since proteins execute the genetic
code and carry out most biological processes, we focus on protein-
protein interaction (PPI) networks. In these networks, nodes
correspond to proteins and undirected edges represent physical
interactions between them.
We have been witnessing the exponential growth of the
amounts of available PPI network data, along with the
development of computational approaches for studying and
modeling of these data. High-throughput screens for interaction
detection, such as yeast two-hybrid (Y2H) assays [2–8], affinity
purification coupled to mass spectrometry (AP/MS) [9–12],
genome-wide chromatin immunoprecipitation, correlated m-
RNA expression, and genetic (synthetic-lethal) and suppressor
networks [13,14], have yielded partial networks for many model
organisms [2–5,11–13] and humans [6,7], as well as for bacterial
[15–17] and viral [18–20] pathogens. Numerous biological
network datasets are now publicly available in several databases,
including Saccharomyces Genome Database (SGD) [21], the
Database of Interacting Proteins (DIP) [22], Human Protein
Reference Database (HPRD) [23], and the Biological General
Repository for Interaction Datasets (BioGRID) [24].
Proteins are essential macromolecules of life, and hence,
understanding their function and their role in disease is of
importance. Since proteins aggregate to perform a function
instead of acting in isolation, and since PPI networks model
interactions between proteins, analyzing PPI network topology is
expected to uncover new biology. Therefore, it is not surprising
that prediction of protein function [25–27] and the role of protein
networks in disease [1,28–32] from the topology of PPI networks
have received attention in the post-genomic era.
Nonetheless, there is still a debate about whether network
properties of ‘‘biologically central’’ genes or proteins, such as those
involved in aging, cancer and infectious diseases caused by
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influenza), exhibit some ‘‘topological centrality’’ compared to the
rest of the proteins in the PPI network [1,28–31,33–35]. Many
approaches have focused on examining only simple topological
properties of these proteins, such as their direct neighborhoods in a
PPI network. For example, the key assumption of many studies is
that proteins that are direct neighbors are more likely to perform
the same function than those that are not [25,26], or that a
neighbor of a disease-causing gene is likely to cause either the same
or a similar disease [1,34]. Another example is the observed
correlation between a protein’s essentiality and its degree centrality
(the larger the degree of a node, the more ‘‘degree-central’’ the
node) in a PPI network of baker’s yeast [36]. However, the
controversy arose in the light of newer and more complete PPI
network data for which this correlation was not observed [37,38]
and it appears to hold only for literature-curated [39] and smaller
in scope Y2H PPI networks [3], possibly because these data sets
are biased towards essential proteins [38]. Also, degree alone
might be a weak measure of network topology, as it captures
limited network topology, i.e., only direct neighborhood of a node
[27,31,40]. A similar controversy arose when cancer genes were
initially shown to have greater connectivities and centralities
compared to non-cancer genes, indicating central roles of cancer
genes within the interactome [33], but it was later demonstrated
that most of disease genes do not show a tendency to code for
proteins that are hubs [29], although a recent study again reached
the conclusion that cancer proteins have different network
topologies, e.g., higher degrees, than ‘‘control’’ genes [35]. Apart
from this, general conclusions are that disease genes have high
connectivity and are centrally positioned within the PPI network
[1]. In addition, it has been suggested that aging genes tend to
have higher degrees than non-aging ones [41,42], as well as that
the majority of viral and bacterial pathogens show tendency to
interact with high-degree proteins, or with ‘‘bottleneck’’ proteins
that are central to many paths in the PPI network [43].
Measures of network topology that are more constraining than
degrees might help resolve these controversies. Hence, various
topological centrality concepts have been formulated. Examples
include the betweenness centrality [35], according to which nodes that
occur in many of the shortest paths in a network have high
centrality, and the subgraph centrality, which counts the number of
closed walks of different lengths in the network starting and ending
at the node in question and according to which nodes that
participate in a large number of such walks have high centrality
[44,45].
In addition, we have recently designed a graphlet-based
measure of network topology; graphlets are small induced subgraphs
of a large network [46,47]. As opposed to partial subgraphs (e.g.,
network motifs [48]), graphlets are induced, meaning that they
contain all edges between the nodes of the subgraph that are
present in the large network. This measure generalizes the degree
of a node that counts the number of edges that the node touches,
where an edge is the only 2-node subgraph, into the graphlet degree
vector (GDV) that counts the number of different graphlets that the
node touches, for all 2–5-node graphlets. Hence, GDV of a node
describes the topology of its up to 4-deep neighborhood. This is an
effective measure: going to distance of 4 around a node captures a
large portion of a network due to the small-world nature of many
real networks [49]. For this reason, and since the number of
graphlets on n nodes increases exponentially with n, we believe
that using larger graphlets would unnecessarily increase the
computational complexity of the method. We designed the
similarity measure between GDVs of different nodes, GDV-
similarity, to quantify the topological similarity of the extended
neighborhoods of two nodes. We used this constraining measure of
network topological similarity to demonstrate that: in PPI
networks, biological function of a protein and its local network
structure are closely related [27,50]; from topology of PPI
networks we can extract biological information that cannot always
be extracted from sequence and hence, topology could be used as
a complementary method to sequence-based methods for
homology detection [51]; topology around cancer and non-cancer
genes is different and can be used to successfully predict new
cancer genes in melanogenesis-related pathways [31,40]; purely
topological network alignments can be used to extract protein
function and species phylogeny [52,53].
This study
Here, we present novel network-based approaches applied
towards a deeper understanding of biological function and disease.
We aim to further study and understand currently poorly
described mechanisms by which ‘‘biologically central’’ genes
interact with each other and with other genes in the cell. We
define as biologically central (BC) the genes that belong to one of the
following four gene categories: aging (A) genes, cancer (C) genes,
HIV-interacting (HIV) genes, and pathogen-interacting (PI) genes.
Our hypothesis is that BC genes, i.e., their protein products
(henceforth, we use terms ‘‘gene’’ and ‘‘protein’’ interchangeably),
will have a topologically central role in the human PPI network.
We use two different concepts to define ‘‘topological centrality’’:
graphlet degree centrality and domination (defined below).
Previously, we defined GDV-similarity of nodes’ neighborhoods
that is independent of the densities of these neighborhoods: nodes
with identical GDVs have the maximum GDV-similarity,
regardless of whether they reside in dense or sparse neighbor-
hoods. Here, we propose a new centrality measure, graphlet degree
centrality (GDC), to measure the density and complexity of nodes’
neighborhoods by counting the number of different graphlets that
the node touches. According to GDC, nodes in dense and complex
4-deep neighborhoods will have higher centralities than nodes in
sparse 4-deep neighborhoods. GDC is a different and more
constraining measure of network topology than the degree
centrality (DC), as illustrated in Figure 1: GDC ranks highly a
low-degree gene if its 4-deep neighborhood is dense and gives a
low rank to a high-degree gene if its 4-deep neighborhood is sparse
(details are below). GDC is conceptually different than the
betweenness centrality (BWC), which does not measure topolog-
ical denseness at all. Subgraph centrality (SC) measures the
number of closed walks (which can be thought of as partial
subgraphs) that the node touches and it has been shown to be
more highly correlated with the lethality of proteins in the PPI
network of baker’s yeast than DC [44]. Unlike SC, GDC counts
induced subgraphs rather than partial ones and in a more rigorous
way: while SC counts an edge that a node touches many times, as
a 2-edge closed walk (going from node A to node B along edge AB
and returning from B to A along the same edge), as a 4-edge closed
walk (going from node A to node B and back to A twice), as a 6-
edge closed walk (going from A to B and back to A three times)
etc., GDC counts the edge only once and only as an edge, rather
than as different subgraph structures.
For each of the four centrality measures (DC, BWC, SC, and
GDC), we identify the most central genes (explained below) in the
human PPI network [28] and measure the enrichment of these genes
in BC genes (i.e., the percentage of the most central genes that are
BC genes), with the goal of finding the centrality measure that is
the most discriminative in uncovering BC genes; ideally, the most
discriminative measure would have all of the most central genes to
be BC genes. We find that: (1) enrichments in BC genes of the
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GDC-central genes, (2) the observed enrichments in BC genes of
the most GDC-central genes are statistically significant, while
those of non-GDC-central genes are not, (3) BC genes that are
GDC-central have higher and statistically significant enrichments
in known drug targets than BC genes that are non-GDC-central,
and (4) GDC is at least as discriminative as the next best centrality
measure.
Second, we hypothesize that genes that are vital for normal
cellular functioning might correspond to the ‘‘spine’’ of the
network that connects all parts of the network. The field of
telecommunications and the domain of the efficient design of
routing protocols for wireless networks in particular, uses the
notion of a dominating set (DS) to find the most central set of nodes
in wireless networks that would be used for efficient data routing
and lead to bandwidth increase and energy savings; in wireless
networks, nodes correspond to computers and routers, and edges
correspond to links between them [54–57]. A dominating set of a
network is a set of nodes such that every node in the network is
either in the DS or is a direct neighbor of a node in the DS.
Hence, the nodes in the dominating set act as a ‘‘gateway’’ in the
network, since all nodes in the network are at most one step away
from them and the transfer of the information to all nodes can be
quick and cheap. The challenge is to identify a minimum order
DS, a DS of the minimum size (i.e., the minimum number of
nodes). This problem is NP-hard. Thus, approximate (heuristic)
algorithms are sought.
Given the topologically central role of nodes in a DS, we
hypothesize that a good DS algorithm might capture a set of
proteins in a PPI network that are involved in important biological
processes and mechanisms crucial for cell vitality, i.e., that DSs of
PPI networks might contain BC proteins and signaling pathways
(SPs). We test this by constructing a connected dominating set in
the human PPI network with an algorithm that is commonly used
in telecommunications [57]. We are interested in connected DSs
only since signaling pathways are connected. Other algorithms for
finding connected DSs are used in telecommunications as well
(e.g., [54,56,58,59]), but are not applicable to biological networks,
because they require nodes to be assigned meaningful numerical
IDs, e.g., IP addresses in computer networks; clearly, proteins in
PPI networks do not have numerically meaningful labels. Also,
several algorithms for finding disconnected (i.e., independent; see
Methods) DSs exist [60,61], but they are inappropriate for our
study for the above mentioned reasons. In addition to applying the
existing DS algorithm of Rai et al. [57], we design a new and
simpler DS algorithm that outperforms the algorithm of Rai et al.
on our data (explained below). Note that the main focus of this
study is not to create a state-of-the-art algorithm for finding DSs,
but instead, to demonstrate, as a proof of concept, that a DS of a
PPI network found by a very simple algorithm indeed captures
biologically vital proteins. Any further algorithmic improvements
are likely to yield more optimal DSs and hence improve the
biological results.
We apply DS algorithms to the human PPI network [28] and
measure the size of the resulting DSs, as well as their enrichments
in BC and SP genes. We find that: (1) the enrichments in BC and
SP genes of nodes of DSs are much higher than the enrichments of
nodes outside of DSs; (2) the enrichments in BC and SP genes of
nodes of DSs are statistically significant, while those of nodes
outside of DSs are not; and (3) BC and SP genes that are in DSs
have much higher and statistically significant enrichments in
known drug targets than BC and SP genes that are not in DSs.
Hence, we confirm our hypothesis that DSs capture biologically
vital proteins and also drug targets.
Furthermore, we demonstrate not only that each of the two
measures of topological centrality, GDC and DS, captures a
Figure 1. An illustration of the differences between DC and GDC. Left: Direct neighborhood of ZAP90, a cancer and HIV gene, in the human
PPI network [28]. Its degree is 48 and it is ranked as the top 187th gene with respect to DC. Right: Direct neighborhood of PRKACA, an HIV gene, in the
network. Its degree is 145 and it is ranked as the top 20th gene with respect to DC. Both proteins have the same GDC and are ranked as top 92nd
genes with respect to GDC. Hence, GDC rewards the ranking of a low-degree gene if its 4-deep neighborhood is dense (ZAP90) and penalizes the
ranking of a high-degree gene if its 4-deep neighborhood is sparse (PRKACA). (For the esthetics of the figure, we only show 1-deep neighborhoods.)
doi:10.1371/journal.pone.0023016.g001
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genes (as described above), but also that the combination of the
two centralities is even more discriminative in capturing these
genes. To our knowledge, this is the first study that uses
dominating sets to analyze PPI networks.
Methods
Data sets
We analyze the human PPI network of Radivojac et al. that
contains 41,456 physical interactions between 9,141 proteins [28],
as well as the human PPI networks from BioGRID [24], that
contains 30,513 physical interactions between 8,581 proteins, and
from HPRD [23], that contains 36,811 physical interactions
between 9,449 proteins (we downloaded them in June 2010). Since
we obtained qualitatively similar results for all three networks, for
simplicity we report only on the PPI network of Radivojac et al.
[28]; we chose this network, since it has the largest number of
interactions.
As mentioned above, biologically central (BC) genes that we
analyze include: aging, cancer, HIV, and pathogen-interacting
genes. We obtained them from the following databases. Aging genes
(A) are human genes implicated in the process of aging that are
available from AnAge Databank - Human Ageing Genomic
Resources (http://genomics.senescence.info/) [62]. Cancer genes (C)
are human genes implicated in cancer that are available from:
Cancer Gene Database (http://ncicb.nci.nih.gov/projects/cgdcp),
Cancer Genome Project – the Cancer Gene Census (http://www.
sanger.ac.uk/genetics/CGP/Census/) [63], GeneCards (http://
www.genecards.org/) [64], Kyoto Encyclopedia of Genes and
Genomes (KEGG) (http://www.genome.jp/kegg/disease/) [65],
and Online Mendelian Inheritance in Man (OMIM) (http://www.
ncbi.nlm.nih.gov/sites/entrez?db=omim) [66]. HIV genes (HIV)
are human genes known to interact with genes of the HIV virus
[63] that are available from HIV-1-Human Protein Interaction
Database (http://www.ncbi.nlm.nih.gov/RefSeq/HIVInterac-
tions/) [67]. Finally, pathogen-interacting genes (PI) are human genes
known to interact with genes of pathogens [43]. The data are
downloaded in 2009 and 2010.
In the human PPI network, there are 2,101 BC genes in total, of
which 237 are aging genes, 887 are cancer genes, 1,132 are HIV
genes, and 500 are PI genes. Figure 2 illustrates the overlap of
different BC gene categories in the network. The overlap is low
and there are only 20 BC genes that are simultaneously aging,
cancer, HIV, and PI genes.
Signaling pathways (SPs) that we analyze include the human:
MAP kinase interactome [68], cancer and immune pathways from
NetPath [69], and all human signaling pathways from KEGG
[65]. The data are downloaded in November 2010. In the PPI
network, there are 2,253 SP genes, 911 of which are also BC
genes. Given that there is a total of 2,101 BC genes in the network,
the total number of BC and SP genes together is
2253z2101{911~3443.
The drug target data was downloaded from DrugBank [70].
Centrality measures
Related work. Several notions of node centrality have been
used in the past. Degree centrality (DC) of a node is the number of its
neighbors, i.e., its degree. Alternatively, DC can be normalized by
dividing the degree with n{1, where n is the number of nodes in
the network. Betweenness centrality (BWC) of a node is the sum, over
all node pairs i and j in the network, of the percentage of all
shortest paths between i and j in the network that go through the
node of interest. Subgraph centrality (SC) of a node is a weighted sum
of the numbers of all closed walks of different lengths in the
network starting and ending at the node. These closed walks are
related to partial subgraphs of a network, e.g., a closed walk with
four nodes can ‘‘go through’’ different subgraphs on four nodes,
such as along the same edge AB twice (as described above: from
node A to node B along edge AB, then back to A along the same
edge and then again from A to B and back to A along the same
edge), or along a 4-node cycle ABCD that includes edge AB (along
the ‘‘square’’ from node A to node B to node C to node D and
back to A; this is regardless of whether edges CA and DB that ‘‘go
along the diagonal of the square’’ exist) etc. The above mentioned
sum is weighted so that the contribution of the closed walks
decreases as the length of the walks increases, i.e., shorter walks
(smaller subgraphs) have higher weight.
Graphlet degree centrality. We introduce a new node
centrality measure as follows. Graphlets are small, connected,
induced, non-isomorphic subgraphs of a large network (Figure 3
A) [46,47]. Previously, we generalized the degree of a node, that
counted how many edges the node touched, into the graphlet degree
vector (GDV), that counted how many graphlets of a given type,
such as a triangle or a square, the node touched (Figure 3 B) [27].
In Figure 3 B, this is illustrated by a node being touched by an
edge (the leftmost illustration), a triangle (the middle illustration),
or a square (the rightmost illustration). More precisely, coordinates
of a GDV count how many times a node is touched by a particular
symmetry group (automorphism orbit, see [47] for details) within a
graphlet (Figure 3 B). Clearly, the degree of a node is the first
coordinate in GDV, since an edge is the only 2-node graphlet.
There is a total of 73 orbits in all 2–5-node graphlets. Thus, the
GDV of a node, describing its up to 4-deep neighborhood (i.e., 2–
5-node graphlets around it), has 73 coordinates [27]. An example
of a GDV of a node that contains all 73 orbits can be found in
[52].
We introduce a new node centrality measure, graphlet degree
centrality (GDC), which measures the density of the node’s extended
network neighborhood. Hence, nodes that reside in dense
extended network neighborhoods will have higher GDCs than
nodes that reside in sparse extended network neighborhoods. In
particular, we define GDC as follows. For a node v, we denote by
vi the ith coordinate of its GDV, i.e., vi is the number of times node
v touches an orbit i. Then, GDC of node v is computed as follows:
Figure 2. The overlap of BC genes from the four categories in
the human PPI network.
doi:10.1371/journal.pone.0023016.g002
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X 72
i~0
wi|log(viz1),
where wi is the weight of orbit i that accounts for dependencies
between orbits, as in [27]; e.g., counts of orbit 3, a triangle, will
affect counts of all orbits that contain a triangle. Hence, for each
orbit, we count how many orbits affect it and assign a higher
weight wi (wi[½0,1 ) to the orbits that are not affected by many
other orbits (see [27] for details). We use log in the formula
because the coordinates i and j of the GDV of node v can differ by
several orders of magnitude and we do not want the GDC to be
entirely dominated by orbits with very large values. We add 1 to vi
in the formula to prevent the logarithm function to go to infinity
for an orbit count of 0. Finally, we scale the value of the GDC(v)
to (0,1] by dividing it with the maximum GDC(u) over all nodes u
in the network.
Algorithms for finding dominating sets
Let G(V,E) be a network, where V is the set of nodes of G and
E is the set of edges of G.Adominating set (DS) of graph G is a
subset S(V of the nodes such that for all nodes v[V, either v[S
or a neighbor u of v is in S. A dominating set is said to be minimal if
it contains no proper subset that is dominating and it is said to be
minimum if it is of the smallest cardinality. The cardinality of a
minimum dominating set of graph G, c(G), is called the domination
number of G. It has been shown that for graph G with jVj nodes:
q
jVj
1zdmax(G)
rƒc(G)ƒjVj{dmax(G), ð1Þ
where dmax (G) is the maximum node degree in G [60]. Identifying
a minimum DS is NP-hard, and hence, approximate (heuristic)
algorithms are sought.
Heuristic algorithms result in either an independent DS or a
connected DS. A subset P of V is said to be an independent set if no
two vertices in P are adjacent. A connected DS is a DS in which
each node is connected to at least one other node that is in the DS.
(Note that if a graph consists of several connected components, a
DS of such a graph would be connected within each component,
but disconnected across components.) In the context of biological
networks, we are interested in connected DSs.
First, we implement an existing algorithm by Rai et al. for
constructing a connected DS of graph G(V,E) that is commonly
used in telecommunications [57]. We call this algorithm ‘‘DS-
RAI’’. It consists of three phases: (1) constructing an independent
DS named S, (2) finding a set of nodes C(V\S to connect nodes
in S by constructing the Steiner tree between the nodes in S, and
(3) pruning the DS defined on nodes S|C to reduce the number
of nodes in the DS. More specifically, the algorithm works as
follows. In phase 1, each node is colored white. A white node u
that is connected to most other white nodes is taken from V,
colored black meaning that it is a ‘‘dominator,’’ and added to S.
All neighboring nodes of u are colored gray meaning that they are
‘‘dominatees’’ and added to V\S. Previous steps are repeated on
the remaining white nodes in V until all nodes of V are either
colored black and added to S, or colored gray and added to V\S.
In phase 2, a gray node from V\S that is connected to the largest
number of black nodes in S is selected, colored dark gray meaning
it is a ‘‘connector,’’ and added to C. The algorithm then checks
whether node set S|C is connected and if so, it stops; otherwise,
the algorithm selects the next gray node from V\S that is
connected to the largest number of black nodes in S and repeats
the entire process until node set S|C becomes connected. In
phase 3, ‘‘redundant’’ nodes are deleted from the connected DS
defined on S|C to reduce its size as follows. Let G½V’  denote a
subgraph of G induced on a subset of nodes V’(V. The
algorithm selects a node u with the minimum degree in G½S|C 
and checks whether the DS defined on S|C\fug remains a
Figure 3. Graphlets, automorphism orbits, and GDVs. (A) All 9 graphlets with 2, 3 and 4 nodes, denoted by G0, G1,…,G8; they contain 15
topologically unique node types, called automorphism orbits, denoted by 0, 1, 2, …, 14. In a particular graphlet, nodes belonging to the same orbit
are of the same shade (see [47] for details). (B) An illustration of the GDV of node v; it is presented in the table for orbits 0 to 14: v is touched by 4
edges (orbit 0), end-nodes of 2 graphlets G1 (orbit 1), etc. The figure is taken from [53].
doi:10.1371/journal.pone.0023016.g003
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Otherwise, it remains in S|C. This is repeated for all nodes in
S|C, in the order of their increasing degrees. The node set
resulting from node removals from S|C in step 3 is the final DS
produced by DS-RAI algorithm. An illustration is presented in
Figure 4 A.
The algorithm breaks all ties uniformly at random. Interestingly,
the algorithm is robust to this randomness: we run the algorithm
on the human PPI network 30 times using different random seeds,
which results in 94.2% overlap between the resulting 30 DSs. The
average DS size over the 30 runs is 1,817+1 nodes, out of which
1,711 (i.e., 94.2%) appear in all of the 30 DSs. Hence, given that
such a large proportion of any DS is in all DSs, any DS is
representative of all of them. Therefore, we continue further
analyses of one of the DSs.
Next, we introduce a new, simple, one-step algorithm for
constructing a connected DS, that we call ‘‘DS-DC’’: it starts with
S~V, selects a node u with the minimum degree in G½S , removes
u from S only if the DS defined on S\fug remains a connected DS
of G, and repeats the above steps for all nodes in S in order of their
increasing degrees. An illustration is presented in Figure 4 B.
Clearly, DS-DC is much simpler than DS-RAI. Also, as illustrated
in Figure 4, DS-DC results in a smaller DS than DS-RAI (the
same holds for real-world PPI networks, as demonstrated in
Section 0). Finally, we introduce a modification of DS-DC in
which nodes from S are visited in order of their increasing GDCs
instead of degrees, which we call ‘‘DS-GDC’’ algorithm.
Statistical significance of enrichments
For a given protein set X of size jXj, we measure its enrichment
in BC (and SP) genes. We compute the statistical significance (p-
value) of observing a given enrichment by measuring the
probability that the same enrichment would be observed in a
randomly chosen set of jXj proteins in the PPI network. This
probability is computed as follows by using the following notation:
the total number of proteins in the network is jVj; the number of
proteins in set X is jXj; the number of proteins in set X that are
BC (SP) genes is jfj; there are jFj proteins in the entire PPI
network that are BC (SP) genes. Then, the enrichment is jfj=jXj,
and the p-value, i.e., the probability of observing the same or
higher enrichment purely by chance, is obtained by using the
hypergeometric distribution formula for sampling without replace-
ment:
p{value~1{
X jfj{1
i~0
jFj
i
  
jVj{jFj
jXj{i
  
jVj
jXj
   : ð2Þ
Results and Discussion
GDC captures BC genes
For each of the four centralities (DC, BWC, SC, and GDC) and
each of the four categories of BC genes (A, C, HIV, and PI), we
find in the human PPI network the top k% of the most central
genes (k~1,2,3,:::,100%) and measure how many BC genes they
contain. For example, we measure how many cancer genes (C) are
in the top 1%, the top 2%, the top 3% etc. most central genes with
respect to each of the four centrality measures. We do the same for
aging (A), HIV, and PI genes. For a given centrality measure, BC
gene category, and k, we quantify the accuracy of the centrality
measure in capturing BC genes by computing precision and recall.
Precision can be seen as a measure of exactness: it is the
percentage of the top k% of the most central genes that are BC
genes. Recall can be seen as a measure of completeness: it is the
percentage of BC genes of the network that are in the top k%o f
the most central genes. We need to determine a threshold for k
that results in the best combination of precision and recall. Since
when varying the values of k, every decrease in precision
corresponds to increase in recall, we choose as the threshold for
k the point where precision and recall cross (Figure 5). We do this
for each of the four centrality measures and each of the four BC
gene categories. If the threshold is found to be K, we denote as
‘‘central’’ those genes that are amongst the top K% of the most
central genes and as ‘‘non-central’’ all the remaining genes in the
network. We find that the thresholds are 3, 10, 12, and 6, for A, C,
HIV, and PI genes, respectively, for each of the four centrality
measures.
We compute the BC gene enrichments of central and non-
central genes. We find that with respect to GDC, enrichments in
each of the four BC gene categories are much higher for central
genes, ranging between 23.5% and 36.4%, than enrichments for
Figure 4. An illustration of DSs in a toy network. The DSs were
obtained by (A) DS-RAI and (B) DS-DC algorithms. The example in panel
A is taken from [57], and the authors describe the algorithm as follows.
In phase 1, nodes 1, 4, 8, 12, and 16 are colored black as members of an
independent DS. In phase 2, nodes 2, 9, and 11 are colored dark grey as
connectors that connect nodes in the independent DS resulting from
phase 1. In phase 3, the connected DS resulting from phase 2 is pruned
to reduce it size by removing node 16 from the DS (no other nodes can
be removed without violating the requirement of producing a
connected DS of the graph). In panel B, all nodes are initially in the
DS and then nodes are visited in order of their increasing degrees and
removed from the DS if the resulting DS is a valid connected DS of the
graph. That is, nodes are removed in the following order: 3, 16, 2, 4, 7,
10, 13, 14, 15, and 9. The resulting DS therefore contains the remaining
nodes: 1, 5, 6, 8, 11, and 12. Clearly, the DS produced by DS-DC (black
nodes in panel B) is smaller than the DS produced by DS-RAI (black and
dark grey nodes in panel A).
doi:10.1371/journal.pone.0023016.g004
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These enrichments are statistically significant for central genes,
with p-valuesƒ10{11, while for non-central genes they are not,
with p-values~1 (see Methods). As expected, if we choose lower k,
e.g., 1%, precision is even higher (although recall is lower): out of
the top 1%~91 of the most GDC-central proteins in the network,
55% (i.e., 47 of them) are aging genes, 45% (i.e., 41 of them) are
cancer genes, 71.5% (i.e., 65 of them) are HIV genes, and 42.9%
(i.e., 39 of them) are PI genes (Figure 7).
Also, we measure the enrichment in drug targets of BC genes
(i.e., of each of the four BC gene categories: ‘‘A’’, ‘‘C’’, ‘‘HIV’’,
and ‘‘PI’’ defined above) that are GDC-central and of BC genes
that are non-GDC-central. We hypothesize that higher GDC of
nodes in the PPI network reflects their functional importance.
Proteins that are targeted by drugs are clearly functionally
important. Hence, we examine whether the sets of BC genes that
are GDC-central contain more drug targets than the sets of BC
genes that are non-GDC-central. Indeed, we find that enrichments
in drug targets are higher for BC genes that are GDC-central than
for BC genes that are non-GDC-central (Figure 6 B). Further-
more, these enrichments in drug targets are statistically significant
for GDC-central BC genes (with the exception of GDC-central
HIV genes), with p-valuesƒ0:047, while for non-GDC-central BC
genes they are not, with p-values§0:9 (see Methods).
In addition to the above demonstration that GDC captures
statistically significant biological signal, we compare its perfor-
mance against the performance of the three other centrality
measures (DC, BWC, and SC). We do so by determining which
measure is the most discriminative in the sense that it uncovers the
largest number of BC genes amongst the top K% of the most
central genes (K is computed as above) and hence results in the
highest enrichments. As shown in Figure 6 C, GDC is at least as
good as other centrality measures for all categories of BC genes,
except for cancer genes, for which SC has a slightly higher
enrichment, but GDC still outperforms DC and BC. GDC always
outperforms DC, confirming our hypothesis that GDC, as a more
constraining measure of network topology, could capture the
biological signal better. SC also outperforms DC for aging genes,
but interestingly not for HIV and PI genes. Hence, although GDC
and SC both capture deeper network topology than DC and are
conceptually similar in the sense that they both count a number of
subgraphs that a node participates in, unlike GDC, SC is not
always more discriminative than DC.
To evaluate whether GDC captures statistically significant
biological signal and outperforms other centrality measures
irrespective of the chosen thresholds k, for each centrality
measure, we compute the area under precision-recall curve
(AUPR) as the threshold is varied between 0% and 100% in
increments of 1%. The results obtained from AUPRs correspond-
ing to different centrality measures are mostly consistent with the
results obtained at selected thresholds where precision and recall
cross (described above): for HIV and PI genes, AUPRs for GDC
are the highest, followed by AUPRs for DC, SC, and BWC,
respectively; for A and C genes, AUPRs for SC are the highest,
followed by AUPRs for GDC, DC, and BWC, respectively.
Hence, as was the case for individual thresholds (see above), GDC
always outperforms DC, while SC outperforms DC only for A and
C genes. Hence, GDC is always more discriminative than DC,
while SC is not always more discriminative than DC, even though
SC captures a deeper network topology compared to DC. The
values of AUPRs for GDC are: 0.27 for A, 0.2 for C, 0.34 for HIV,
and 0.2 for PI genes. These somewhat law values are not
surprising, since in biological applications, the number of positive
examples (here, the known BC genes) is much smaller than the
number of negative examples (here, all proteins in the network that
are currently not known to be BC genes). Furthermore, we do not
know true negatives (genes that are true non-BC genes). Since we
expect that many currently unreported BC genes will turn out to
be BC genes in the future, AUPRs are likely to increase as this
happens. Moreover, the observed AUPRs are statistically
significant: we compute, at each value of recall, the probability
of observing a given precision and we find that the probabilities of
observing a given number of BC genes among k% of randomly
chosen genes are in the range 0:03{10{13 for k up to 90%
(clearly, for k close to 100%, results become statistically
insignificant, which is expected, since we choose as GDC-central
all genes in the network).
Dominating sets capture BC genes, signaling pathways,
and drug targets
We find DSs in the human PPI network by using the three DS
algorithms described above, DS-RAI, DS-DC, and DS-GC (see
Methods). We find that the overlap between the three resulting
DSs is large, containing 1,720 nodes, out of the total of 1,834
nodes in DS-RAI, 1,815 nodes in DS-DC, and 1,828 nodes in DS-
GC DSs (Figure 8). Both of our algorithms, DS-DC and DS-GDC,
produce smaller DSs than DS-RAI. Also, each of them produces a
DS that captures a huge portion of the DS produced by DS-RAI.
Using GDC to guide our algorithm does not seem to result in a
smaller DS then when we use DC and thus, we continue our
analysis on the DS created by DS-DC.
For the DS created by DS-DC algorithm and for its
complement (the set of proteins in the network that are not in
the DS, ‘‘non-DS’’), we calculate their enrichments in BC genes,
genes that are members of signaling pathways (SP), genes that are
in the union of BC and SP genes (‘‘BC or SP’’), and genes that are
both BC and SP genes (‘‘BC and SP’’). We find that the
enrichments are much higher for the DS than for non-DS (Figure 9
A). Furthermore, the enrichments for the DS are statistically
significant, with p-valuesƒ10{11, while for non-DS they are not,
with p-values~1 (see Methods).
Figure 5. Precision and recall for aging genes in the human PPI
network. They were computed for the top k% of the most GDC-central
genes (k~1,2,:::,100). Here, precision and recall cross at k~3.
doi:10.1371/journal.pone.0023016.g005
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23016Furthermore, we measure the enrichment in drug targets of BC
and SP genes (i.e., of gene categories ‘‘BC’’, ‘‘SP’’, ‘‘BC or SP’’,
and ‘‘BC and SP’’ defined above) that are in the DS, and of BC
and SP genes that are not in the DS. If our hypothesis that the
topological positioning of nodes in the DS indeed reflects their
functional importance is correct, then BC and SP genes that are in
the DS should contain more drug targets than BC and SP genes
that are not in the DS, since proteins that are targeted by drugs are
clearly important for normal cellular functioning. Indeed, we find
that enrichments in drug targets are much higher for BC and SP
genes that are in the DS than for BC and SP genes that are not in
the DS (Figure 9 B). Furthermore, these enrichments for the BC
and SP genes that are in the DS are statistically significant, with p-
valuesƒ10{4, while for SP and BC genes that are not in the DS
they are not, with p-values~0:9998 (see Methods).
Functional analysis of topologically central genes
For each category of BC genes (A, C, HIV, and PI genes), we
compute enrichment of GDC-central and non-GDC-central genes
in each of the Gene Ontology (GO) terms [71]. We consider all
GO terms belonging to each of the three GO categories:
molecular function (MF), biological process (BP), and cellular
component (CC). Of the total of 1,359 MF, 3,925 BP, and 736 CC
GO terms present in the human PPI network, 117 MF, 379 BP,
and 27 CC GO terms are statistically significantly enriched (see
Methods) in all 4 BC gene categories of GDC-central genes, while
4 MF, 10 BP, and 4 CC GO terms are statistically significantly
enriched in non-GDC-central genes. Interestingly, there is no
overlap between GO terms that are enriched in central genes and
GO terms that are enriched in non-central genes.
Similar results are obtained for central and non-central genes
with respect to membership in the dominating set (DS). DS-central
genes are statistically significantly enriched in 153 MF, 574 BP,
and 44 CC GO terms, while non-DS-central genes are statistically
significantly enriched in 7 MF, 7 BP, and 0 CC GO terms, with no
overlap between GO terms of central and non-central genes.
Hence, central genes appear to group by functions that are
different than functions of non-central genes. Biological functions
with the most significant enrichments that are present among all
groups of central genes (but none of which is present among any of
the groups of non-central genes) include many processes critical for
normal cellular functioning, such as: regulation of cell cycle,
Figure 7. The top 1% (i.e., 91) GDC-central genes. If a gene is an aging (‘‘A’’), cancer (‘‘C’’), HIV (‘‘HIV’’), or pathogen-interacting (‘‘PI’’) gene, there
is an ‘‘X’’ in the corresponding entry.
doi:10.1371/journal.pone.0023016.g007
Figure 6. The performance of GDC and its comparison with other centrality measures. (A) Enrichments in BC genes of the top k% of the
most GDC-central genes (denoted by ‘‘Central’’, blue bars) and all remaining genes (denoted by ‘‘Non-central’’, red bars) in the human PPI network.
(B) Enrichment in drug targets of BC genes that are GDC-central (‘‘Central’’) and BC genes that are non-GDC-central (‘‘Non-central’’). (C) Enrichments
in BC genes of the top k% of the most central genes in the human PPI network, with respect to the four centrality measures (DC, BWC, SC, and GDC),
broken into the four BC gene categories (aging (A), cancer (C), HIV (HIV), and pathogen-interacting (PI) genes). In all panels, the values of k where
precision and recall cross (as illustrated in Figure 5) are used; k equals 3, 10, 12, and 6, for A, C, HIV, and PI genes, respectively, for each of the four
centrality measures.
doi:10.1371/journal.pone.0023016.g006
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innate immune response, regulation of cell differentiation, signal
transduction, activity of many signaling pathway cascades (e.g.,
MAPK, I-kappaB kinase/NF-kappaB, EGFR, FGFR, IGFR,
androgen receptor, nerve growth factor receptor, T cell receptor,
toll-like receptor, etc.), phosphorylation, response to DNA
damage, blood coagulation, regulation of cell proliferation, T cell
activation and co-stimulation, response to tumor necrosis factor,
response to drug, interspecies interaction between organisms etc.
Implications
GDC captures the density and topological complexity of up to
4-deep network neighborhood around a node. Since we have
demonstrated significant enrichment of GDC-central proteins in
BC genes, this means that genes that are involved in key biological
processes occupy topologically complex and dense parts of the
human PPI network. Similarly, since we have demonstrated
significant enrichment of DSs in BC and SP genes, this indicates
that proteins that are vital for normal cellular functioning reside on
the ‘‘spine’’ of the network that dominates, i.e., connects, all other
parts of the network. Hence, the notion of network domination
seems to capture the topology required for passing cellular signals
efficiently throughout the network.
We hypothesize that GDC-central proteins and proteins in DSs
of PPI networks could represent potential candidates for therapeutic
intervention, since targeting GDC-central proteins with drugs
would have more significant impacts on the network than targeting
proteins that reside in sparse and non-complex network regions and
since the topology of a DS can enable quick propagation of drug
effects through the entire network. Indeed, we find that the
enrichment in drug targets of genes that are GDC-central or are in
the DS (this is the union of the set of genes that are GDC-central
and the set of genes that are in the DS) is 11.4% and it is statistically
significant, with p-value of 1:3|10{4. Furthermore, the enrich-
ment in drug targets of genes that are simultaneously GDC-central
and are in the DS (this is the intersection of the set of genes that are
GDC-central and the set of genes that are in the DS) is even higher,
it is 31.7%; this enrichment is also statistically significant, with p-
value of 0. Hence, not only that each of the two concepts of
topological centrality, GDC and DS, captures a statistically
significant percentage of drug targets, but also when the two
centralities are combined, the percentage of drug targets that they
capture is significant and even higher.
Concluding remarks
We propose a new centrality measure, graphlet degree centrality
(GDC), to simultaneously measure the density and complexity of a
node’s extended neighborhood by counting the number of
different graphlets that the node touches. We find that: (1) the
enrichments in BC genes are much higher for GDC-central genes
than for non-GDC-central genes; (2) the observed enrichments are
statistically significant for GDC-central genes, while for non-
GDC-central genes they are not; (3) BC genes that are GDC-
central have higher and statistically significant enrichments in
known drug targets than BC genes that are non-GDC-central; and
(4) GDC outperforms other centrality measures in the sense that it
uncovers the largest number of BC genes among the most central
genes and is thus the most discriminative centrality measure.
Given the topologically central role of nodes in a DS, we apply
to the human PPI network an existing DS algorithm that is
commonly used in telecommunications, with the hypothesis that a
DS might capture a set of proteins in a PPI network that are
involved in important biological processes and mechanisms crucial
for cell vitality. Also, we design a new and simpler DS algorithm
that outperforms the existing algorithm on our data. We
emphasize that our main focus is not to create a state-of-the-art
algorithm for finding DSs, but instead, to demonstrate, as a proof
of concept, that a DS of a PPI network found by a very simple
Figure 9. ‘‘Biological centrality’’ of the DS. (A) Enrichment in BC
and SP genes of the dominating set (‘‘DS’’) and its complement (‘‘non-
DS’’) in the human PPI network. (B) Enrichment in drug targets of BC
and SP genes that are in the dominating set (‘‘DS’’) and BC and SP genes
that are not in the dominating set (‘‘Non-DS’’).
doi:10.1371/journal.pone.0023016.g009
Figure 8. Overlap of the three DSs created by DS-RAI, DS-DC,
and DS-GDC algorithms applied to the human PPI network.
doi:10.1371/journal.pone.0023016.g008
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(1) the enrichments in BC and SP genes are much higher for nodes
of DSs than for nodes outside of DSs; (2) the observed enrichments
are statistically significant for nodes of DSs, while for nodes outside
of DSs they are not; (3) BC and SP genes that are in DSs have
much higher and statistically significant enrichments in known
drug targets than BC and SP genes that are not in DSs; and (4)
GDC-central genes that are also in the DS contain the highest,
statistically significant percentage of drug targets.
These results imply that nodes in dense and complex
neighborhoods that dominate the network are vital for normal
cellular functioning and signaling. Hence, they might be targets for
new therapeutic exploitation. Further algorithmic improvements
would aid in more precise identification of these new targets.
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